Sonoma BioTherapeutics
Sonoma BioTherapeutics is a clinical-stage biotechnology company focused on developing engineered regulatory T cell therapies for autoimmune and inflammatory diseases, with proprietary technologies and a new manufacturing facility in Seattle.
Services
Sonoma BioTherapeutics focuses on developing engineered regulatory T cell (Treg) therapies aimed at treating autoimmune and inflammatory diseases. Utilizing proprietary platform technologies, the company offers targeted and durable Treg cell therapies. They have initiated Phase 1 studies for both Treg therapy and Teff biologics.
Founders
Sonoma BioTherapeutics was founded by pioneers in Treg biology and cell therapy. Leveraging their extensive expertise in these fields, the founders set out to develop innovative solutions for autoimmune and inflammatory diseases.
Products
Sonoma BioTherapeutics is developing several novel therapies, including SBT-77-7101, a regulatory T cell-based therapy targeting rheumatoid arthritis and hidradenitis suppurativa. Another key product is SBT-11-5301, an effector T Cell-modulating biologic designed to address a range of autoimmune diseases.
Partnerships
Sonoma BioTherapeutics has partnered with Regeneron to discover, develop, and commercialize novel regulatory T cell (Treg) therapies. This collaboration leverages both companies' strengths in biotechnology to advance therapeutic options for autoimmune and inflammatory conditions.
Manufacturing and Facilities
Sonoma BioTherapeutics utilizes a proprietary manufacturing process to ensure robust yields of engineered Treg cells. The company is also building its own manufacturing facility in Seattle to support the development and production of its therapies. Their operational bases are located in South San Francisco and Seattle.